Case reports in oncology · 2026
Integrative Oncology Approach in Advanced Myxofibrosarcoma: A Case Report of Prolonged Survival with High-Dose Vitamin C and Viscum album.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gigineishvili David, Rukhadze Tamar, Orange Maurice
Аннотация
INTRODUCTION: Myxofibrosarcoma (MFS) is a rare and aggressive soft tissue sarcoma with high recurrence and metastasis rates. The prognosis in advanced metastatic disease is poor, with median survival time ranging from 12 to 24 months despite multimodal therapy. Integrative oncology approaches, such as high-dose vitamin C and Viscum album, are increasingly explored as adjuncts in both curative and palliative cancer care.
CASE PRESENTATION: We present the case of a 59-year-old male with high-grade unresectable MFS of the right buttock and spinal metastases. Standard palliative treatments (systemic chemo- and radiotherapy, followed by targeted and immunotherapy) were combined with high-dose intravenous vitamin C and V. album extracts given intravenously, subcutaneously, and intratumorally. Despite the progression of the disease and COVID-19 comorbidity, the patient survived for 48 months, exceeding conventional survival estimates.
CONCLUSION: This case suggests that integrative oncology combining systemic anticancer therapy with high-dose vitamin C and V. album extracts may enhance tolerance and extend survival in advanced MFS. Further prospective studies are warranted to corroborate the value of complementary therapy in sarcoma management.
CASE PRESENTATION: We present the case of a 59-year-old male with high-grade unresectable MFS of the right buttock and spinal metastases. Standard palliative treatments (systemic chemo- and radiotherapy, followed by targeted and immunotherapy) were combined with high-dose intravenous vitamin C and V. album extracts given intravenously, subcutaneously, and intratumorally. Despite the progression of the disease and COVID-19 comorbidity, the patient survived for 48 months, exceeding conventional survival estimates.
CONCLUSION: This case suggests that integrative oncology combining systemic anticancer therapy with high-dose vitamin C and V. album extracts may enhance tolerance and extend survival in advanced MFS. Further prospective studies are warranted to corroborate the value of complementary therapy in sarcoma management.